source
- Gilead's HIV prevention shot Yeztugo posts $232 million Q2 sales, beating forecastsGilead reported that its biannual injectable for HIV pre‑exposure prophylaxis, Yeztugo, generated $232 million in revenue during the second quarter. This figure exceeds analysts' consensus estimat…
- AstraZeneca and BMS deny merger talks, Reuters says no dealReuters reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb have been dismissed. A senior source close to the matter told Reuters there is no deal and no discussions betw…